Docstoc

AU

Document Sample
AU Powered By Docstoc
					                                         PROF. RICCARDO ROSSO

                                            Pubblicazioni 2000-2006

BENASSO M.-PONZANELLI A.-MERLANO M.-NUMICO G.-RICCI I.-VIGO V.-GROSSI F.-AMADORI D.-
CAVALLO G.-CAPACCETTI B.-TAVEGGIA P.-BONI L.-ROSSO R.
Paclitaxel, cisplatin and 5/fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from
an italian cooperative group.
Acta Oncol. 45:168/174, 2006
IF 2.362

DE PAOLI A.-CHIARA S.-LUPPI G.-FRISO M.-BERETTA G.-DEL PRETE S.-PASETTO L.-SANTANTONIO M.-
SARTI E.-MANTELLO G.-INNOCENTE R.-FRUSTACI S.-CORVO' R.-ROSSO R.
Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a
multicentric phase II study.
Ann. Oncol. 17:246/251, 2006
IF 4.319

ARDIZZONI A.-FAVARETTO A.-BONI L.-BALDINI E.-CASTIGLIONI F.-ANTONELLI P.-PARI F.-TIBALDI C.-
ALTIERI A.-BARBERA S.-CACCIANI G.-RAIMONDI M.-TIXI L.-STEFANI M.-MONFARDINI S.-ANTILLI A.-
ROSSO R.-PACCAGNELLA A.
Platinum/etoposide chemotherapy in elderly patients with small cell lung cancer: results of a randomized multicenter
phase II study assessing attenuated dose or full dose with lenograstim prophylaxis. A Forza Operativa Nazionale
Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP/GSTPV) study.
J. Clin. Oncol. 23:569/575, 2005
IF 9.835

ARDIZZONI A.-SCOLARO T.-MEREU C.-CAFFERATA M.-TIXI L.-BACIGALUPO A.-TISEO M.-MONETTI F.-
ROSSO R.
Induction chemotherapy with carboplatin/paclitaxel followed by standard radiotherapy with concurrent daily low dose
cisplatin plus weekly paclitaxel for inoperable non small cell lung cancer.
Am. J. Clin. Oncol. 28:58/64, 2005
IF 1.703

BRUZZI P.-DEL MASTRO L.-SORMANI M.-BASTHOLT L.-DANOVA M.-FOCAN C.-FOUNTZILAS G.-PAUL
J.-ROSSO R.-VENTURINI M.
Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients.
J. Clin. Oncol. 23:5117/5125, 2005
IF 9.835

CHIARA S.-NOBILE M.T.-TOMASELLO L.-ACQUATI M.-TAVEGGIA P.-MUROLO C.-PERCIVALE P.L.-
ROSSO R.
Phase II trial of irinotecan and raltitrexed in chemotherapy naïve advanced colorectal cancer.
Anticancer Res. 25:1391/1396, 2005
IF 1.395

DEL MASTRO L.-BRUZZI P.-NICOLO' G.-CAVAZZINI G.-CONTU A.-D'AMICO M.-LAVARELLO A.-
TESTORE F.-CASTAGNETO B.-AITINI E.-PERDELLI L.-BIGHIN C.-ROSSO R.-VENTURINI M.-Other
Partecipants-BOCCARDO F.
HER2 expression and efficacy of dose dense anthracycline containing adjuvant chemotherapy in breast cancer patients.
Br. J. Cancer 93:7/14, 2005
IF 3.742

DEL MASTRO L.-PERRONE F.-REPETTO L.-MANZIONE L.-ZAGONEL V.-FRATINO L.-MARENCO D.-
VENTURINI M.-MAGGI E.-BIGHIN C.-CATZEDDU T.-VENTURINO A.-ROSSO R.
Weekly paclitaxel as first line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo
Italiano di Oncologia Geriatrica (GIOGer).
Ann. Oncol. 16:253/258, 2005
IF 4.335
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)-BRUZZI P.-MONTANARO E.-ROSSO R.-SERTOLI
M.R.-VENTURINI M.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview
of the randomised trials.
Lancet 365:1687/1717, 2005
IF 21.713

GENNARI A.-CONTE P.-ROSSO R.-ORLANDINI C.-BRUZZI P.
Survival of metastatic breast carcinoma patients over a 20 year period. A retrospective analysis based on individual
patient data from six consecutive studies.
Cancer 104:1742/1750, 2005
IF 4.434

SOBRERO A.-FRASSINETI G.-FALCONE A.-DOGLIOTTI L.-ROSSO R.-COSTANZO F.-BRUZZI P.
Adjuvant sequential methotrexate --> 5/fluorouracil vs 5/fluorouracil plus leucovorin in radically resected stage III and
high risk stage II colon cancer.
Br. J. Cancer 92:24/29, 2005
IF 3.742

TWELVES C.-WONG A.-NOWACKI M.-ABT M.-BURRIS H.-CARRATO A.-CASSIDY J.-CERVANTES A.-
FAGERBERG J.-GEORGOULIAS V.-HUSSEINI F.-JODRELL D.-KORALEWSKI P.-KRONING H.-MAROUN J.-
MARSCHNER N.-McKENDRICK J.-PAWLICKI M.-ROSSO R.-SCHULLER J.-SEITZ J.-STABUC B.-
TUJAKOWSKI J.-VAN HAZEL G.-ZALUSKI J.-SCHEITHAUER W.
Capecitabine as adjuvant treatment for stage III colon cancer.
N. Engl. J. Med. 352:2696/2704, 2005
IF 38.570

VENTURINI M.-DEL MASTRO L.-AITINI E.-BALDINI E.-CAROTI C.-CONTU A.-TESTORE F.-BREMA F.-
PRONZATO P.-CAVAZZINI G.-SERTOLI M.R.-CANAVESE G.-ROSSO R.-BRUZZI P.
Dose dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
J. Natl. Cancer Inst. 97:1724/1733, 2005
IF 13.856

BALDINI E.-PROCHILO T.-SALVADORI B.-BOLOGNESI A.-ALDRIGHETTI D.-VENTURINI M.-ROSSO R.-
CARNINO F.-GALLO L.-GIANNESSI P.-CONTE P.-ORLANDINI C.-BRUZZI P.
Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic
breast cancer patients: focus on cardiac safety.
Br. J. Cancer 91:45/49, 2004
IF 3.894

BENASSO M.-CORVO' R.-PONZANELLI A.-SANGUINETI G.-RICCI I.-PALLESTRINI E.-SANTELLI A.-
VITALE V.-ROSSO R.
Alternating gemcitabine and cisplatin with gemcitabine and radiation in stage IV squamous cell carcinoma of the head
and neck.
Ann. Oncol. 15:646/652, 2004
IF 3.605

CAZZANIGA M.-PRONZATO P.-LETO S.-DE MATTEIS A.-DI COSTANZO F.-PASSALACQUA R.-ROSSO R.-
TORRI V.
Patterns of relapse and modalities of treatment of breast cancer: the IRIS Project, a multicenter observational study.
Oncology (Basel) 66:260/268, 2004
IF 2.381

CHIARA S.-NOBILE M.T.-GOZZA A.-TAVEGGIA P.-HEOUAINE A.-PASTRONE I.-PERCIVALE P.L.-
LIONETTO R.-SANGUINETI O.-ROSSO R.
Phase II study of weekly oxaliplatin and high dose infusional 5/fluorouracil plus leucovorin in pretreated patients with
metastatic colorectal cancer.
Anticancer Res. 24:355/360, 2004
IF 1.347
CONTE P.-GUARNERI V.-BRUZZI P.-PROCHILO T.-SALVADORI B.-BOLOGNESI A.-ALDRIGHETTI D.-
VENTURINI M.-ROSSO R.-MAMMOLITI S.-CARNINO F.-GIANNESSI P.-COSTANTINI M.-MOYANO A.-
BALDINI E.
Concomitant versus sequential administration of epirubicin and paclitaxel as first line therapy in metastatic breast
carcinoma. Results from the Gruppo Oncologico Nord Ovest randomized trial.
Cancer 101:704/712, 2004
IF 4.017

O'BRIEN M.-WIGLER N.-INBAR M.-ROSSO R.-GRISCHKE E.-SANTORO A.-CATANE R.-KIEBACK D.-
TOMCZAK P.-ACKLAND S.-ORLANDI F.-MELLARS L.-ALLAND L.-TENDLER C.
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HC1
(CAELYX/Doxil) versus conventional doxorubicin for first line treatment of metastatic breast cancer.
Ann. Oncol. 15:440/449, 2004
IF 3.605

AAPRO M.-VAN WIJK F.-VAN DER BURG M.-TEN BOKKEL W.-VERGOTE I.-GUASTALLA J.-ROSSO R.-
KOBIERSKA A.-BEEX L.-NAMER M.-SPLINTER T.-VERMORKEN J.
Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological
Cancer Group.
Eur. J. Cancer 39:1141/1143, 2003
IF 3.562

BALDINI E.-GARDIN G.-GIANNESSI P.-EVANGELISTA G.-RONCELLA M.-PROCHILO T.-COLLECCHI P.-
ROSSO R.-LIONETTO R.-BRUZZI P.-MOSCA F.-CONTE P.
Accelerated versus standard cyclophosphamide, epirubicin and 5/fluorouracil or cyclophosphamide, methotrexate and
5/fluorouracil: a randomized phase III trial in locally advanced breast cancer.
Ann. Oncol. 14:227/232, 2003
IF 3.114

BENASSO M.-LIONETTO R.-CORVO' R.-PONZANELLI A.-VITALE V.-ROSSO R.
Impact of the treating institution on the survival of patients with head and neck cancer treated with concomitant
alternating chemotherapy and radiation.
Eur. J. Cancer 39:1895/1898, 2003
IF 3.562

DI COSTANZO F.-SOBRERO A.-GASPERONI S.-DOGLIOTTI L.-FRASSINETI L.-FALCONE A.-LIONETTO R.-
BRUZZI P.-LUPPI G.-GALLO L.-CONTE P.-COMANDONE A.-TURCI D.-MARZOLA M.-FOLCO U.-PFANNER
E.-MESTRINER M.-BONI C.-GALLI C.-TONATO M.-ROSSO R.
Adjuvant chemotherapy in the treatment of colon cancer: randomised multicenter trial of the Italian National Intergroup
of Adjuvant Chemotherapy in Colon Cancer (INTACC).
Ann. Oncol. 14:1365/1372, 2003
IF 3.114

GROSSI F.-BELVEDERE O.-ROSSO R.
Geography of clinical cancer research publications from 1995 to 1999.
Eur. J. Cancer 39:106/111, 2003
IF 3.562

REPETTO L.-VANNOZZI M.-HAZINI A.-SESTINI A.-PIETROPAOLO M.-ROSSO R.
Anastrozole and quinapril can be safely coadministered to elderly women with breast cancer and hypertension: a
pharmacokinetic study. Letter.
Ann. Oncol. 14:1587/1588, 2003
IF 3.114

ZANIBONI A.-ARDIZZONI A.-DE MARINIS F.-PORTALONE L.-BONI C.-MERIGGI F.-CAFFERATA M.-
ARIGANELLO O.-TORRI V.-NEUMAIER C.-ROSSO R.
Phase II study of taxol combined with ifosfamide and carboplatin in the treatment of stage IIIb/IV non small cell lung
cancer.
Am. J. Clin. Oncol. 26:84/88, 2003
IF 1.136
BERTELLI G.-VENTURINI M.-DEL MASTRO L.-BERGAGLIO M.-SISMONDI P.-BIGLIA N.-VENTURINI S.-
PORCILE G.-PRONZATO P.-COSTANTINI M.-ROSSO R.
Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast
cancer patients: a randomized study.
Ann. Oncol. 13:883/888, 2002
IF 3.153

CASSIDY J.-TWELVES C.-VAN CUTSEM E.-HOFF P.-BAJETTA E.-BOYER M.-BUGAT R.-BURGER U.-
GARIN A.-GRAEVEN U.-McKENDRICK J.-MAROUN J.-MARSHALL J.-OSTERWALDER B.-PEREZ G.-ROSSO
R.-ROUGIER P.-SCHILSKY R.
First line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous
5/fluorouracil/leucovorin.
Ann. Oncol. 13:566/575, 2002
IF 3.153

DEL MASTRO L.-COSTANTINI M.-MORASSO G.-BONCI F.-BERGAGLIO M.-BANDUCCI S.-VITERBORI P.-
CONTE P.-ROSSO R.-VENTURINI M.
Impact of two different dose intensity chemotherapy regimens on psychological distress in early breast cancer patients.
Eur. J. Cancer 38:359/366, 2002
IF 3.460

PRANDI M.-LIONETTO R.-BINI A.-FRANCIONI G.-ACCARPIO G.-ANFOSSI A.-BALLARIO E.-BECCHI G.-
BONILAURI S.-CAROBBI A.-CAVALIERE P.-GARCEA D.-GIULIANI L.-MORZIANI E.-MOSCA F.-MUSSA A.-
PASQUALINI M.-PODDIE D.-TONETTI F.-ZARDO L.-ROSSO R.
Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy. Results of a
secondary analysis of a large scale adjuvant trial.
Ann. Surg. 235:458/463, 2002
IF 6.674

SANGUINETI G.-SORMANI M.-BENASSO M.-CORVO' R.-FOPPIANO F.-RICCI I.-MARCENARO M.-ROSSO
R.-VITALE V.
Late local treatment morbidity after accelerated radiotherapy or alternating chemoradiotherapy for advanced head and
neck carcinoma.
Tumori 88:313/320, 2002
IF 0.490

VENTURINI M.-DEL MASTRO L.-GARRONE O.-ANGIOLINI C.-MERLANO M.-BERGAGLIO M.-TOLINO G.-
LAMBIASE A.-BALDINI A.-CANAVESE G.-ROSSO R.
Phase I, dose finding study of capecitabine in combination with docetaxel and epirubicin as first line chemotherapy for
advanced breast cancer.
Ann. Oncol. 13:546/552, 2002
IF 3.153

ARDIZZONI A.-CAFFERATA M.-PAGANUZZI M.-FILIBERTI R.-MARRONI P.-NERI M.-FONTANA V.-
NICOLO' G.-PERDELLI L.-GALLO C.-ROSSO R.-PUNTONI R.
Study of pretreatment serum levels of Her 2/neu oncoprotein as a prognostic and predictive factor in patients with
advanced nonsmall cell lung carcinoma.
Cancer 92:1896/1904, 2001
IF 3.611

BALDINI E.-ARDIZZONI A.-PROCHILO T.-CAFFERATA M.-BONI L.-TIBALDI C.-NEUMAIER C.-CONTE P.-
ROSSO R.
Gemcitabine, ifosfamide and navelbine (GIN): activity and safety of a non platinum based triplet in advanced non small
cell lung cancer (NSCLC).
Br. J. Cancer 85:1452/1455, 2001
IF 3.489

BENASSO M.-MERLANO M.-SANGUINETI G.-CORVO' R.-NUMICO G.-RICCI I.-PALLESTRINI E.-SANTELLI
A.-VITALE V.-MARCHETTI G.-ROSSO R.
Gemcitabine, cisplatin, and radiation in advanced, unresectable squamous cell carcinoma of the head and neck. A
feasibility study.
Am. J. Clin. Oncol. 24:618/622, 2001
IF 0.952

CHIARA S.-LIONETTO R.-VINCENTI M.-BRUZZONE M.-NOBILE M.T.-GADDUCCI A.-CARNINO F.-ROSSO
R.-CONTE P.
Advanced ovarian cancer in the elderly: results of consecutive trials with cisplatin based chemotherapy.
Crit. Rev. Oncol. Hematol. 37:27/34, 2001
IF 1.019

CHIARA S.-NOBILE M.T.-VINCENTI M.-GOZZA A.-PASTRONE I.-ROSSO M.-ROSSO R.
Sucralfate in the treatment of chemotherapy induced stomatitis: a double blind, placebo controlled pilot study.
Anticancer Res. 21:3707/3710, 2001
IF 1.331

CORVO' R.-BENASSO M.-SANGUINETI G.-LIONETTO R.-BACIGALUPO A.-MARGARINO G.-PALLESTRINI
E.-MERLANO M.-VITALE V.-ROSSO R.
Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of
the head and neck. Results from a phase III randomized trial.
Cancer 92:2856/2867, 2001
IF 3.611

DEL MASTRO L.-VENTURINI M.-LIONETTO R.-CARNINO F.-GUARNERI D.-GALLO L.-CONTU A.-
PRONZATO P.-VESENTINI L.-BERGAGLIO M.-COMIS S.-ROSSO R.
Accelerated intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in
metastatic breast cancer patients: Results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico
Nord Ovest Mammella Inter Gruppo Group.
J. Clin. Oncol. 19:2213/2221, 2001
IF 8.773

DEL MASTRO L.-VENTURINI M.-VISCOLI C.-BERGAGLIO M.-SIGNORINI A.-BIGHIN C.-BERTELLI G.-
SEMINO C.-PIETRA G.-BERTOGLIO S.-SERTOLI M.R.-LAMBIASE A.-ROSSO R.-MELIOLI G.
Intensified chemotherapy supported by DMSO/free peripheral blood progenitor cells in breast cancer patients.
Ann. Oncol. 12:505/508, 2001
IF 3.249

DI COSTANZO F.-GASPERONI S.-FALCONE A.-DOGLIOTTI L.-FRASSINETTI L.-BRUZZI P.-ROSSO R.
Repetita iuvant INTACC (Intergruppo Italiano Terapia Adiuvante Carcinoma del Colon). Letter.
Ann. Oncol. 12:1331, 2001
IF 3.249

DUFFAUD F.-VAN DER BURG M.-NAMER M.-VERGOTE I.-WILLEMSE P.-TEN BOKKEL W.-GUASTALLA
J.-NOOIJ M.-KERBRAT P.-PICCART M.-TUMOLO S.-FAVALLI G.-VAN DER VANGE N.-LACAVE A.-WILS
J.-SPLINTER T.-EINHORN N.-ROOZENDAAL K.-ROSSO R.-VERMORKEN J.
D/TRP/6/LHRH (triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Cooperative
Group Study.
Anticancer Drugs 12:159/162, 2001
IF 1.570

O'SHAUGHNESSY J.-BLUM J.-MOISEYENKO V.-JONES S.-MILES D.-BELL D.-ROSSO R.-MAURIAC L.-
OSTERWALDER B.-BURGER H.-LAWS S.
Randomized, open label, phase II trial of oral capecitabine (xeloda) vs a reference arm of intravenous CMF
(cyclophosphamide, methotrexate and 5/fluorouracil) as first line therapy for advanced metastatic breast cancer.
Ann. Oncol. 12:1247/1254, 2001
IF 3.249

PARRA H.-TIXI L.-LATTERI F.-BRETTI S.-ALLOISIO M.-GRAVINA A.-LIONETTO R.-BRUZZI P.-DANI C.-
ROSSO R.-COSSO M.-BALZARINI L.-SANTORO A.-ARDIZZONI A.
Combined regimen of cisplatin, doxorubicin, and alpha/2b interferon in the treatment of advanced malignant pleural
mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer
Task Force (FONICAP).
Cancer 92:650/656, 2001
IF 3.611
ROSSO M.-BENASSO M.-ROSSO R.
Chemo radiotherapy in locally advanced squamous cell carcinoma of the head and neck: factors affecting toxicity
patterns.
J. Chemother. 13:648/652, 2001
IF 0.921

VAN CUTSEM E.-TWELVES C.-CASSIDY J.-ALLMAN D.-BAJETTA E.-BOYER M.-BUGAT R.-FINDLAY M.-
FRINGS S.-JAHN M.-MCKENDRICK J.-OSTERWALDER B.-PEREZ G.-ROSSO R.-ROUGIER P.-SCHMIEGEL
W.-SEITZ J.-THOMPSON P.-VIEITEZ J.-WEITZEL C.-HARPER P.
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer:
results of a large phase III study.
J. Clin. Oncol. 19:4097/4106, 2001
IF 8.773

VENTURINI M.-MICHELOTTI A.-PAPALDO P.-DEL MASTRO L.-BERGAGLIO M.-LIONETTO R.-LUNARDI
G.-SGUOTTI C.-FREVOLA L.-DONATI S.-ROSSO R.-COGNETTI F.
Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose finding
study in advanced breast cancer patients.
Ann. Oncol. 12:1097/1106, 2001
IF 3.249

				
DOCUMENT INFO
Shared By:
Categories:
Stats:
views:21
posted:12/12/2010
language:Italian
pages:6